Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27381398 | 0.98 | HRH3 (0.54) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL678406 | 0.98 | HRH3 (0.52) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL7381954 | 0.93 | HRH3 (0.61) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL7282481 | 0.91 | HRH3 (0.65) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL10695730 | 0.91 | HRH3 (0.65) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL7293644 | 0.91 | HRH3 (0.65) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL7281286 | 0.91 | HRH3 (0.65) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL7283494 | 0.91 | HRH3 (0.65) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL7382944 | 0.91 | HRH3 (0.65) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL678971 | 0.91 | HRH3 (0.56) | HRH3SMN1; SMN2CYP1A2MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014160392-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | claimed |
| CN-102095808-B | Analysis method of related substances in Ebastine | CHONGQING HUAPONT PHARM CO LTD | 2014-04-02 | — | — | CN | claimed |
| WO-2005107744-A1 | NERVE DAMAGE | ROELANTS, IVO (BE) | 2005-11-17 | — | — | WO | claimed |
| CN-1230958-A | Oxazolone derivatives and their use as anti-helicobacter pylori agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-10-06 | — | — | CN | claimed |
| CN-112888310-A | Additive for stabilizing polyacrylamide copolymer solutions under high shear conditions | 巴斯夫欧洲公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-109456328-A | 11- replaces 1,6- diaza benzo anthracyclinone derivatives and its synthetic method and application | 广西师范大学 | 2019-03-12 | — | — | CN | disclosed |
| CN-109438445-A | 8- replaces 1,6- diaza benzo anthracyclinone derivatives and its synthetic method and application | 广西师范大学 | 2019-03-08 | — | — | CN | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-20140135319-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0418696-A2 | Derivatives of aminoacids | MERCK PATENT GmbH (DE) | 1991-03-27 | — | — | EP | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
| US-4755522-A | Derivatives of N-[3-(2,4,6-trimethoxybenzoyl)propyl]piperidine, and their use in therapeutics | LABORATOIRE L. LAFON (FR) | 1988-07-05 | — | — | US | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | SGMS2, PHOSPHO1, SGMS1 | HRH3 2658/4885SMN1; SMN2 4746/4885CYP1A2 1243/4885 |
| US-20140135319-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TK1, CDK1, CDKL1 | HRH3 1499/4885SMN1; SMN2 1787/4885CYP1A2 1317/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | HRH3 2395/4885SMN1; SMN2 985/4885CYP1A2 4232/4885 |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | HRH3 2395/4885SMN1; SMN2 985/4885CYP1A2 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.